Drugs / PF-07224826
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05905341 | Jan 2024 → Apr 2026 | breast cancer, endometrial cancer, liposarcoma, non-small cell lung carcinoma +1 | Pfizer | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07224826 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905341 ↗ |
| Action | Inhibit | “Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6” NCT05905341 ↗ |
| Modality | Small molecule | “Small molecule cell cycle checkpoint inhibitor” NCT05905341 ↗ |
| Route | Oral | “PF-07224826 will be administered orally” NCT05905341 ↗ |